便携式生物分子制造
Keith Pardee1, Shimyn Slomovic2, Peter Q Nguyen3
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.
Cell
|September 24, 2016
概括
这项研究引入了一个便携式合成生物学平台,用于现场按需制造治疗药物和生物分子. 无细胞系统克服了生产和分销方面的局限性, 让人们可以更广泛地获得必要的医疗工具.
科学领域:
- 合成生物学
- 生物技术
- 分子制造
背景情况:
- 目前的合成生物学应用需要专门的设备和制冷,这限制了低资源环境的可访问性.
- 基于细胞的疗法和生物分子的分销面临着重大后勤挑战,特别是在偏远或服务不足的地区.
研究的目的:
- 利用合成生物学开发一个便携式的现场制造平台,用于治疗和生物分子.
- 克服生产有价值的生物化合物的专用设备和冷链需求的局限性.
主要方法:
- 基于含有冷干燥的无细胞转录和翻译机器的灵活系统的开发.
- 按需生物合成通过加水颗粒和添加编码所需产品的DNA来启动.
- 抗菌和疫苗的制造和功能验证.
主要成果:
- 使用便携式平台成功地在现场按需生产抗菌和疫苗.
- 证明了生产抗体合物和小分子的组合方法.
- 验证系统解决治疗和生物分子生产的实际限制的能力.
结论:
- 开发的合成生物学平台使治疗药物和生物分子的分散制造成为可能.
- 这项技术在发达地区和发展中国家显著改善了基本医疗工具的可用性.
- 该系统为按需生物合成提供了可持续和可适应的解决方案,解决了全球关键的健康需求.
更多相关视频
07:35Rapid, Enzymatic Methods for Amplification of Minimal, Linear Templates for Protein Prototyping using Cell-Free Systems
Published on: June 14, 2021
3.2K
08:50Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
1.5K
相关概念视频
Upstream Processing
97
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
97
Production of Pharmaceuticals
94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94
